On Nov. 13, 2017, the Department of Transportation (DOT) published a final rule that, among other items, expands DOT’s current drug testing panel to include certain semi-synthetic opioids (i.e., hydrocodone, oxycodone, hydromorphone, oxymorphone). Testing for methylenedioxyethylamphetamine (MDEA) has been removed while methylenedioxyamphetamine (MDA) has been added as an initial test analyte.
The final rule also clarifies existing drug testing program provisions and definitions, makes technical amendments and removes the requirement for employers and Consortium/Third Party Administrators to submit blind specimens. The final rule becomes effective Jan. 1, 2018.
“The opioid crisis is a threat to public safety when it involves safety-sensitive employees involved in the operation of any kind of vehicle or transport,” said DOT Secretary Elaine L. Chao. “The ability to test for a broader range of opioids will advance transportation safety significantly and provide another deterrence to opioid abuse, which will better protect the public and ultimately save lives.”
Click here to read more from DOT.
Click here to read the final rule as published in the Federal Register.
Related News
- Tesla sparks safety showdown with nation’s rail workers
- Public Comment of SMART-TD Regarding Tesla’s Special Permit Request for Transporting Lithium Batteries by Rail
- SMART officers boost advocacy with redesigned New Representatives II class
- Operation Lifesaver campaigns to promote rail safety in 11 states
- New TD Crew Room Flyers Available
- Colorado bill criminalizing transit assault one step closer to becoming law
- Honoring the Legacy of Brother John A. Saunders
- Colorado Transit Worker Safety Bill (House Bill 25-1290)
- Kansas funds passenger rail expansion
- SMART’s General President Defends Our Brother